Table 2 Days Alive and Free of organ dysfunction and artificial organ support by Loss-Of-Function (LOF) genotype of PCSK9. More days alive and free of organ failure or organ support is a beneficial outcome so PCSK9 LOF is associated with less organ failure.

From: Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients

PCSK9 LOF

No LOF

LOF

P

(n = 154)

(n = 146)

Days alive and free

Organ dysfunction

  Cardiovascular

9 (0–22)

20 (3–25)

0.001

  Respiratory

2 (0–16)

6 (0–20)

0.025

  Renal

12 (1–28)

25 (10–28)

<0.001

  Hematologic

21 (2–28)

26 (10–28)

0.004

  Hepatic

19 (3–28)

28 (10–28)

0.002

  Neurologic

12.5 (1–24)

19 (6–27)

0.005

Artificial support

  Vasopressor use

13 (0–23)

21 (3–25)

0.003

  Ventilator

2 (0–18)

12 (0–21)

0.016

  Renal replacement therapy

14 (2–28)

28 (12–28)

<0.001

Overall days alive

28 (1–28)

28 (1–28)

<0.0005

  1. Data are median (interquartile range).
  2. p values were calculated using a MannWhitney U test.
  3. Organ dysfunction was recorded as positive if the patient met the SOFA organ dysfunction criteria (>1) that day with the platelet threshold of 80. The number of days out of 28 where a patient is alive with no documented organ dysfunction is a Day Alive and Free of organ dysfunction.
  4. Organ failure scores were only available for cohort 1 and 2, hence the lower n compared to Table 1.
Back to article page